Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2a Human Challenge Trial (HCT) to test Ampligen as a potential intranasal prophylactic antiviral therapy using a human Rhinovirus hRV (common cold virus) and Influenza

Next Previous
Trial Profile

A phase 2a Human Challenge Trial (HCT) to test Ampligen as a potential intranasal prophylactic antiviral therapy using a human Rhinovirus hRV (common cold virus) and Influenza

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rintatolimod (Primary)
  • Indications Influenza B virus infections; Rhinovirus infections
  • Focus Therapeutic Use
  • Sponsors AIM ImmunoTech

    • Most Recent Events

    • 30 Sep 2021 According to an AIM ImmunoTech media relrease, company and hVIVO have a signed Clinical Trial Agreement (CTA) for this trial.
    • 20 Sep 2021 According to an AIM ImmunoTech media release, the proposed protocol for the study was submitted to the Oxford Research Ethics Committee (REC)/Medicines and Healthcare Regulatory Agency (MHRA) on September 10, 2021. A meeting is scheduled to review the study on September 24, and the response is expected by mid November. In addition, AIM and hVIVO (CRO) continue to work to finalize the details of a Clinical Trial Agreement (CTA).
    • 14 Jul 2021 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top